“…14 The trial reported a 2.2% rate of early adverse events that included device embolization, arteriovenous fistula, cardiac perforation, pericardial effusion with cardiac tamponade, and major hemorrhage requiring transfusion. Even with the use of broader definitions to include ischemic stroke and other vascular complications, the complication rate is significantly lower than that reported by Badheka et al, 16 4.2% versus 24%, which is at least partly explained by the methodological issues noted. Finally, as noted by the authors, the study is further limited by the inability to identify complication rates for each individual device.…”